HomePrevencio Inc.

Prevencio Inc.

Prevencio Announces Two Validation Studies Confirming High Accuracy of Novel HART AI-driven Tests

3/18/19: Researchers believe these important findings, presented March 17 at the 2019 American College of Cardiology (ACC) Scientific Sessions in New Orleans, demonstrate the robustness and accuracy of these tests. The new data, from two additional hospitals, confirm results previously published from Massachusetts General Hospital and Dr. James Januzzi.

New Prevencio Study Using AI Demonstrates Novel Blood Test Accurately Predicts Acute Kidney Injury Risk

11/12/18: In this study, researchers evaluated the company’s AI-driven HART AKI test on 889 patients undergoing cardiac catheterization in Massachusetts General Hospital’s (MGH) Catheter Sampled Blood Archive in Cardiovascular Disease (CASABLANCA) study.

Data Demonstrating HART PAD™ Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patients

8/27/18: The study is follow-on to data presented at the American Diabetes Association (ADA) 2018 Scientific Sessions in June 2018 demonstrating Prevencio's HART CAD™ and HART CVE™ tests accurately diagnose coronary artery disease (CAD) and predict the risk for major adverse cardiac events (MACE) in DM patients. Similar to CAD, PAD is commonly due to atherosclerosis, a plaque buildup in the arteries which restricts blood flow.

New Prevencio Study Using AI Demonstrates Simple Blood Test Accurately Diagnoses Aortic Stenosis

3/7/18: Prevencio, Inc., today announces its HARTTM AS multi-protein, artificial intelligence (AI)-driven test, which data indicates accurately diagnoses Aortic Stenosis (AS)—a condition with a 50 percent death rate when left untreated.